Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has announced the immediate appointment of Rebecca Jolley as Senior Vice President Americas Commercial, Oncology Business Group. Ms. Jolley will lead Eisai's Americas Oncology Commercial team in creating and driving commercial strategies for the company's approved products, pipeline assets and late-stage compounds approaching the commercialization stage. In addition to her functional responsibilities, she will serve as a member of the Eisai Inc. Executive Committee.
"Our objective is to provide the very best customer service in the industry with an unrivaled passion for patients," said Gary Hendler, Chief Commercial Officer of Eisai's Oncology Business Group. "Rebecca has had tremendous success in launching oncology brands, developing and collaborating on disease awareness initiatives, implementing return-to-growth strategies, and leading large cross-functional teams in working together to deliver high quality value to customers and patients. We are confident that Rebecca's extensive experience and proven leadership will help drive the growth of Eisai's oncology business in the Americas, and ensure that all appropriate on label patients have rapid and sustained access to our innovative cancer medicines."
Ms. Jolley joins Eisai from Novartis, where she spent 24 years in a variety of increasingly responsible roles, including sales, market access, marketing, brand leadership and general management. She started her career with Novartis in the UK, then transferred to the U.S. to join Novartis Oncology. During her tenure, she held a number of executive leadership roles that included Vice President, Oncology General Manager for Australia and New Zealand; Vice President, US Oncology Marketing; Vice President, Global Disease Leader Chronic Myeloid Leukemia; and Vice President and Head, Cardiovascular & Respiratory Business Unit.
Ms. Jolley is a graduate of Lancaster University in England, where she holds a BSc Honors First Class in Geography and Biological Sciences. She has been a member of the Healthcare Businesswomen's Association (HBA) since 2005.